Eisai Co.,Ltd. FY2027 Q1 Earnings Report

Quick View

Executive Summary

Revenue and profit increased in the quarter. Strong growth and improved profitability in overseas segments, including the Americas, EMEA, and China, drove higher earnings, while Operating Cash Flow temporarily turned negative due to an increase in working capital. Revenue was ¥234.33B (¥202.65B in the same period of the previous year, YoY +15.6%), Operating Income was ¥24.73B (¥20.74B, YoY +19.2%), and Net Income attributable to owners of the parent was ¥18.24B (¥14.47B, YoY +26.0%). The main drivers of revenue growth were strong growth in the Americas (YoY +22.3%), EMEA (+24.4%), and China (+16.6%). Combined with lower SG&A and R&D expense ratios, this improved the Operating Income margin to 10.6% (10.2% in the previous year). Profit Before Tax was ¥25.28B (¥22.40B in the previous year, YoY +12.8%), with higher finance costs somewhat offsetting the increase in Operating Income.

Factors Affecting Results

【Revenue】Revenue was ¥234.33B (YoY +15.6%). By region, the Americas was the largest and primary growth driver at ¥86.6B (37.0% of total, YoY +22.3%), followed by Japan at ¥57.9B (24.7% of total, +3.4%), China at ¥42.5B (18.2% of total, +16.6%), EMEA at ¥23.6B (10.1% of total, +24.4%), and East Asia and Global South at ¥20.2B (8.6% of total, +25.3%). While domestic growth was relatively moderate, overseas regions generally achieved double-digit growth, and the overseas revenue ratio continued to expand. Other businesses contracted to ¥3.4B (YoY -18.4%).

【Profit and Loss】Operating Income was ¥24.73B (YoY +19.2%), exceeding revenue growth, and the Operating Income margin improved to 10.6% (10.2% in the previous year). Although the gross margin declined by 0.8pt to 78.2% (79.0% in the previous year), the SG&A expense ratio decreased to 49.0% (49.4% in the previous year), while the R&D expense ratio also declined to 18.7% (19.1% in the previous year), with improved cost efficiency contributing to the higher margin. On a segment profit basis, the structure is such that ¥116.08B (¥95.35B in the previous year) from total reported segments, less R&D expenses of ¥38.88B and corporate administrative expenses and other costs of ¥53.72B (including ¥44.25B in profit-sharing payments for anticancer drugs), results in Operating Income of ¥24.73B. Profit Before Tax was ¥25.28B (¥22.40B in the previous year, YoY +12.8%), with finance costs more than doubling to ¥1.96B (¥0.92B in the previous year), partially offsetting profit growth. Net Income attributable to owners of the parent was ¥18.24B (YoY +26.0%), aided by a decline in the effective tax rate to 24.3% (31.6% in the previous year). Revenue and profit increased.

Segment Analysis

The Pharmaceutical Business consists of five regional segments: Japan, the Americas, China, EMEA, and East Asia/Global South. The Americas was the largest source of earnings, with revenue of ¥86.6B and segment profit of ¥51.9B (a 60.0% margin). Its increase in profit (+¥10.39B, YoY +25.0%) was also the largest among all segments. EMEA’s profit margin improved by +9.5pt to 52.7% (43.1% in the previous year), while profit growth of YoY +51.8% was the highest among all segments. China maintained a profit margin of 49.8%, the second-highest level after the Americas, and profit increased by YoY +18.2%. Japan recorded relatively moderate growth compared with other regions, with revenue up YoY +3.4% and profit up YoY +8.1%; its profit margin of 36.3% was also relatively low. East Asia and Global South continued to achieve strong revenue growth of YoY +25.3%, while the profit margin declined to 46.9% (51.1% in the previous year), indicating a slight slowdown in profit growth relative to revenue growth.

Key Financial Metrics

【Profitability】The Operating Income margin improved to 10.6% (10.2% in the previous year), while the Net Income margin, based on income attributable to owners of the parent, improved to 7.8% (7.1% in the previous year). ROE was 2.1% (based on quarterly results, before annualization). 【Cash Flow Quality】Operating Cash Flow was -¥2.59B, significantly below Net Income attributable to owners of the parent of ¥18.24B, indicating that the increase in working capital is weighing on cash generation. 【Investment Efficiency】Capital expenditures of ¥4.26B were approximately 0.45 times depreciation and amortization expense of ¥9.42B. This indicates a cautious investment stance during the quarter, while the R&D expense ratio of 18.7% demonstrates a continued level of R&D investment. 【Financial Soundness】The Equity Ratio declined slightly to 58.2% (62.0% in the previous year), reflecting an increase in interest-bearing debt. However, with a current ratio of approximately 2.24 times and cash and cash equivalents of ¥311.74B exceeding total interest-bearing debt of ¥271.34B, the Company remains in a net cash position and its financial base is generally sound.

Cash Flow Analysis

Operating Cash Flow was -¥2.59B (＋¥1.09B in the previous year). Despite recording Profit Before Tax of ¥25.28B, changes in working capital—accounts receivable +¥26.12B, inventories +¥24.46B, and accounts payable +¥11.64B—absorbed cash, causing OCF to turn negative. Investing Cash Flow was +¥6.46B (-¥9.37B in the previous year), mainly because proceeds of ¥10.91B from the sale and redemption of financial assets exceeded capital expenditures of ¥4.26B and other outflows. Financing Cash Flow was +¥57.92B (+¥26.09B in the previous year), as financing proceeds from a net increase in short-term borrowings of ¥34.01B and the issuance of bonds and ¥50.00B in long-term borrowings exceeded dividend payments of ¥22.57B. Free Cash Flow (Operating Cash Flow + Investing Cash Flow) was +¥3.87B, but fell short of dividend payments of ¥22.57B, with the shortfall funded through borrowings. As a result, cash and cash equivalents increased to ¥311.74B at quarter-end (¥245.42B at the end of the previous fiscal year), strengthening liquidity.

Quality of Earnings

The source of Operating Income was regional segment earnings from the Pharmaceutical Business. The impairment loss of ¥1.31B recorded in the same period of the previous year did not recur in the current period, and no material one-off gains or losses were identified. Below Operating Income, finance income of ¥2.51B and finance costs of ¥1.96B were recorded. Finance costs more than doubled from ¥0.92B in the previous year, reflecting an increase in borrowings. Comprehensive income was ¥31.18B (¥30.26B attributable to owners of the parent). The ¥12.02B difference from Net Income attributable to owners of the parent of ¥18.24B was mainly attributable to foreign currency translation adjustments for foreign operations of +¥14.38B, a foreign-exchange factor separate from business earnings. From an accruals perspective, OCF was below Net Income, and the accumulation of accounts receivable and inventories delayed the conversion of earnings into cash. Accordingly, the quality of earnings for the period was somewhat weak in terms of cash backing.

Earnings Outlook and Guidance

Progress against the full-year earnings forecasts was 26.5% for Revenue (¥234.33B/¥883.50B), 35.3% for Operating Income (¥24.73B/¥70.00B), and 34.9% for Net Income (¥18.24B attributable to owners of the parent/forecast of ¥52.30B). All exceeded the simple quarterly progress benchmark of 25%. The full-year forecasts incorporate substantial profit growth toward the second half of the fiscal year, with Operating Income forecast to increase YoY +58.6% and consolidated Net Income forecast to increase YoY +35.6%. The current quarter’s results—Operating Income YoY +19.2% and Net Income attributable to owners of the parent YoY +26.0%—represent growth ahead of these forecasts. As of the current quarter, no revisions had been made to the earnings or dividend forecasts.

Shareholder Returns

The full-year dividend forecast is ¥160 per share, representing a Payout Ratio of approximately 86.5% against forecast EPS of ¥185. Compared with the previous fiscal year’s actual dividend of ¥80 per share, the forecast dividend of ¥160 represents an increase. Dividend payments during the quarter were ¥22.57B (the same amount as in the previous year), while share repurchases were minimal at ¥0.002B, making dividends the main form of shareholder returns. Free Cash Flow of ¥3.87B during the quarter was below dividend payments, and recovery in OCF will be key to securing funding for shareholder returns over the full year.

Risk Factors

1. Temporary negative Operating Cash Flow due to an increase in working capital: Operating Cash Flow was -¥2.59B during the quarter, mainly due to increases of +¥26.12B in accounts receivable and +¥24.46B in inventories. The increase in accounts payable was limited to +¥11.64B and did not fully offset these outflows.

2. Decline in the gross margin due to foreign-exchange and product-mix fluctuations: The gross margin was 78.2%, down 0.8pt from 79.0% in the previous year. As the overseas revenue mix expands, including the Americas’ 37.0% share, sensitivity to foreign-exchange fluctuations may increase.

3. Increase in finance costs accompanying higher interest-bearing debt: Total interest-bearing debt increased to ¥271.34B (¥186.08B at the end of the same period of the previous year), while finance costs increased to ¥1.96B (¥0.92B in the previous year). The increase was driven by the issuance of bonds and ¥50.00B in long-term borrowings, as well as a net increase of ¥34.01B in short-term borrowings.

Industry Benchmark (For Reference; Compiled by the Company)

Profitability and Returns

The Operating Income margin is below the industry median, while the Net Income margin exceeds the median, indicating different industry positioning at the operating and bottom-line levels.

Growth and Capital Efficiency

The Revenue growth rate is significantly above the industry median and represents a high level of growth within the industry.

Source: Compiled by the Company

Key Earnings Highlights

1. In addition to the trend of higher revenue and profit, growth in highly profitable overseas segments such as the Americas, EMEA, and China drove an improvement in the Operating Income margin (10.2% in the previous year → 10.6%). The diversification of the regional portfolio represents a qualitative change in the earnings structure.

2. Full-year progress was 26.5% for Revenue, 35.3% for Operating Income, and 34.9% for Net Income, all exceeding the quarterly benchmark of 25%. The start toward achieving the full-year forecasts was favorable.

3. On the other hand, Operating Cash Flow was negative (-¥2.59B), creating a gap with Net Income attributable to owners of the parent of ¥18.24B. The primary cause was an increase in working capital, making cash-generation trends from the next quarter onward a key structural focus.

Theoretical Share Price (Reference Value)

This is a reference range mechanically calculated solely from publicly disclosed data using a residual income model (Ohlson-type model with an explicit five-year fade period). It is not a forecast of the market share price or a recommendation of any specific investment action.

Sensitivity: ¥2,888–¥3,048 at ±1% for the cost of equity, and ¥2,959–¥2,972 at ±0.1 for ω.

Notes:

• Because forecast ROE is below the cost of equity, the theoretical value is below book value per share.
• Net assets as of the quarter-end are used (there is a timing difference relative to the full-year forecast).

(Calculation model: Residual Income Model / Interest rate reference month: 2026-06 / This value does not forecast or guarantee future share prices)

---

This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly available earnings data. Investment decisions should be made at your own responsibility, after consulting with professionals as necessary.

---End of Report---